Spero Therapeutics Stock Forecast
NASDAQ: SPROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:27 AM ET
SPRO analyst consensus
Consensus (2 analysts)
none
Avg. price target
$5.00+331.03%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 2 Wall Street analysts covering Spero Therapeutics (2026-10-09), 1 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $5.00, with a high estimate of $6.00 and a low estimate of $4.00. The average target implies upside of 331.0% from the current price of $1.16.
The spread between the highest and lowest targets is 50.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SPRO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 50% |
| Hold | 1 | 50% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | +244.83% |
| Average target | $5.00 | +331.03% |
| High target | $6.00 | +417.24% |